About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

DLBCL >  ASCO 2012 - Diffuse Large B-cell Lymphoma

Last update: 05/31/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

 

  1. A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  2. Treatment for frail elderly patients with diffuse large B-cell lymphoma (DLBCL): A single center experience. | 2012 ASCO Annual Meeting Abstracts

     
  3. The utility of serum lactate dehydrogenase (LDH) in the follow-up of patients with diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  4. Radioimmunotherapy efficiency and safety in consolidation and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An updated analysis of 230 patients of the international RIT-network. | 2012 ASCO Annual Meeting Abstracts

     
  5. PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  6. Effect of radioimmunotherapy-based conditioning for autologous stem cell transplantation on poor-risk molecular profiling in diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  7. Disruption of the eIF4F translation initiation complex as a determinant of diffuse large B-cell lymphoma responsiveness to enzastaurin (LY317615.HCl) and its primary metabolite (LY326020). | 2012 ASCO Annual Meeting Abstracts

     
  8. Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90 (IT-Y90) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  9. Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNHL). | 2012 ASCO Annual Meeting Abstracts

     
  10. Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  11. Clinical significance of nuclear kappa B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  12. Association of prior rituximab exposure among patients undergoing autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma with inferior outcomes in males compared with females. | 2012 ASCO Annual Meeting Abstracts

     
  13. Primary CNS lymphoma: A review of clinicopathologic characteristics, therapy, and outcomes of 54 patients with primary CNS DLBCL. | 2012 ASCO Annual Meeting Abstracts

     
  14. Final results of phase I/II trial of vorinostat in combination with cyclophosphamide, etoposide, prednisone, and rituximab (R-CVEP) for elderly patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  15. Determinants of and outcomes associated with chemoimmunotherapy dose density in elderly subjects with diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  16. Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. | 2012 ASCO Annual Meeting Abstracts

     
  17. Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL). | 2012 ASCO Annual Meeting Abstracts

     
  18. Prognostic impact of immunohistochemically defined germinal center B-cell and nongerminal center B-cell subtypes of diffuse large B-cell lymphoma in rituximab era. | 2012 ASCO Annual Meeting Abstracts

     
  19. Outcome in different molecular subtypes of diffuse large B-cell lymphoma: Indian experience. | 2012 ASCO Annual Meeting Abstracts

     
  20. Expression of mTOR in diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  21. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study. | 2012 ASCO Annual Meeting Abstracts

     
  22. Biweekly regimen of nonpegylated liposomal doxorubicin with cyclophosphamide, vincristine, and prednisone plus rituximab (R-COMP-14) as primary treatment for diffuse large B-cell lymphoma (DLBCL): Long-term follow-up of a phase II study. | 2012 ASCO Annual Meeting Abstracts

     
  23. A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  24. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. | 2012 ASCO Annual Meeting Abstracts

     
  25. Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  26. Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL). | 2012 ASCO Annual Meeting Abstracts

     
  27. What is the significance of CCR5 status in HIV-associated non-Nodgkin lymphoma (NHL)? | 2012 ASCO Annual Meeting Abstracts

     
  28. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). | 2012 ASCO Annual Meeting Abstracts


     
  29. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). | 2012 ASCO Annual Meeting Abstracts

     
  30. Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL. | 2012 ASCO Annual Meeting Abstracts

     
  31. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. | 2012 ASCO Annual Meeting Abstracts

     
  32. CHOP chemotherapy plus rituximab compared with CHOP alone in patients with diffuse large B-cell lymphoma, from Indian subcontinent. | 2012 ASCO Annual Meeting Abstracts

     
  33. A review of clinicopathologic characteristics, therapy, and outcomes of 22 patients with aggressive B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  34. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. | 2012 ASCO Annual Meeting Abstracts

     
  35. Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Children's Oncology Group. | 2012 ASCO Annual Meeting Abstracts

     
  36. Absolute lymphocyte count (ALC), absolute monocyte count (AMC), and ALC/AMC ratio to predict outcome in aggressive non-Hodgkin lymphoma (aNHL). | 2012 ASCO Annual Meeting Abstracts

     
  37. Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia. | 2012 ASCO Annual Meeting Abstracts

     
  38. Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  39. Occult hepatitis B and occult hepatitis C viremia in patients with hematologic malignancies. | 2012 ASCO Annual Meeting Abstracts

     
  40. Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNHL. | 2012 ASCO Annual Meeting Abstracts

     
  41. MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study. | 2012 ASCO Annual Meeting Abstracts

     
  42. R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts
     
  43. Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. | 2012 ASCO Annual Meeting Abstracts 
  44. AIDS-related lymphoma (ARL) in Asians in the era of HAART and rituximab. | 2012 ASCO Annual Meeting Abstracts

     
  45. Association of low expression of VEGF121 soluble isoform with prognostic impact and survival in patients with activated B-cell-like (ABC-like) diffuse large B-cell lymphoma (DLBCL) from the CORAL trial. | 2012 ASCO Annual Meeting Abstracts

     

 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.